The anticancer immune response: indispensable for therapeutic success?

被引：555

作者：

Zitvogel, Laurence ^{[1
,3
,4
]}

Apetoh, Lionel ^{[1
,4
]}

Ghiringhelli, Francois ^{[1
,3
]}

Andre, Fabrice

Tesniere, Antoine ^{[2
,4
]}

Kroemer, Guido ^{[2
,4
]}

机构：

[1] Inst Gustave Roussy, INSERM, U805, F-94805 Villejuif, France

[2] INSERM, U848, Villejuif, France

[3] CIC BT507, Villejuif, France

[4] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 06期

关键词：

D O I：

10.1172/JCI35180

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 [基础医学];

摘要：

Although the impact of tumor immunology on the clinical management of most cancers is still negligible, there is increasing evidence that anticancer immune responses may contribute to the control of cancer after conventional chemotherapy. Thus, radiotherapy and some chemotherapeutic agents, in particular anthracyclines, can induce specific immune responses that result either in immunogenic cancer cell death or in immunostimulatory side effects. This anticancer immune I response then helps to eliminate residual cancer cells (those that fail to be killed by chemotherapy) or maintains micrometastases in a stage of dormancy. Based on these premises, in this Review we address the question, How may it be possible to ameliorate conventional therapies by stimulating the anticancer immune response? Moreover, we discuss the rationale of clinical trials to evaluate and eventually increase the contribution of antitumor immune responses to the therapeutic management of neoplasia.

引用

页码：1991 / 2001

页数：11

共 129 条

[1]

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer [J].

Antonia, SJ ;

Mirza, N ;

Fricke, I ;

Chiappori, A ;

Thompson, P ;

Williams, N ;

Bepler, G ;

Simon, G ;

Janssen, W ;

Lee, JH ;

Menander, K ;

Chada, S ;

Gabrilovich, DI .

CLINICAL CANCER RESEARCH, 2006, 12 (03) :878-887

[2]

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Criollo, Alfredo ;

Ortiz, Carla ;

Lidereau, Rosette ;

Mariette, Christophe ;

Chaput, Nathalie ;

Mira, Jean-Paul ;

Delaloge, Suzette ;

Andre, Fabrice ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

IMMUNOLOGICAL REVIEWS, 2007, 220 :47-59

[3]

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[4]

Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Williams, Kirsten M. ;

Gulley, James L. .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 :4957-4971

[5]

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].

Arbour, NC ;

Lorenz, E ;

Schutte, BC ;

Zabner, J ;

Kline, JN ;

Jones, M ;

Frees, K ;

Watt, JL ;

Schwartz, DA .

NATURE GENETICS, 2000, 25 (02) :187-+

[6]

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer [J].

Arlen, PM ;

Gulley, JL ;

Parker, C ;

Skarupa, L ;

Pazdur, M ;

Panicali, D ;

Beetham, P ;

Tsang, KY ;

Grosenbach, DW ;

Feldman, J ;

Steinberg, SM ;

Jones, E ;

Chen, C ;

Marte, J ;

Schlom, J ;

Dahut, W .

CLINICAL CANCER RESEARCH, 2006, 12 (04) :1260-1269

[7]

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D Ligands by the histone deacetylase inhibitor sodium valproate [J].

Armeanu, S ;

Bitzer, M ;

Lauer, UM ;

Venturelli, S ;

Pathil, A ;

Krusch, M ;

Kaiser, S ;

Jobst, K ;

Smirnow, I ;

Wagner, A ;

Steinle, A ;

Salih, HR .

CANCER RESEARCH, 2005, 65 (14) :6321-6329

[8]

ASAO T, 1992, CANCER RES, V52, P6254

[9]

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma:: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J. ;

Kirchner, H. ;

Rebmann, U. ;

Soder, M. ;

Gertenbach, U. ;

Siebels, M. ;

Roigas, J. ;

Raschke, R. ;

Salm, S. ;

Schwindl, B. ;

Mueller, S. C. ;

Hauser, S. ;

Leiber, C. ;

Huland, E. ;

Heinzer, H. ;

Siemer, S. ;

Metzner, B. ;

Heynemann, H. ;

Fornara, P. ;

Reitz, M. .

BRITISH JOURNAL OF CANCER, 2006, 95 (04) :463-469

[10]

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination [J].

Badovinac, VP ;

Messingham, KAN ;

Jabbari, A ;

Haring, JS ;

Harty, JT .

NATURE MEDICINE, 2005, 11 (07) :748-756

← 1 2 3 4 5 6 7 8 9 10 →